1 / 7

Elbasvir + Grazoprevir Treatment in HCV GT1 and Renal Disease

This study evaluates the efficacy and safety of Elbasvir and Grazoprevir in the treatment of Hepatitis C Virus (HCV) Genotype 1 (GT1) in patients with chronic renal disease. The results show promising outcomes for both treatment-naïve and treatment-experienced individuals.

maudie
Download Presentation

Elbasvir + Grazoprevir Treatment in HCV GT1 and Renal Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 Treatment Naïve and Treatment Experienced Elbasvir + Grazoprevir in GT 1 and Chronic Renal DiseaseC-SURFER Roth D, et al. Lancet 2015;386:1537-45.

  2. Elbasvir + Grazoprevir in HCV GT1 and Renal DiseaseC-SURFER Study: Features Source: Roth D, et al. Lancet 2015;386:1537-45.

  3. Elbasvir + Grazoprevirin HCV GT1 and Renal DiseaseC-SURFER Study: Study Design 0 12 16 40 24 28 Week TNTEGT 1 Stage 4 or 5 CKD Immediate TreatmentEBZ + GRZ N=111 SVR12 Deferred TherapyEBZ + GRZ Deferred TherapyPlacebo SVR12 N=113 Intensive PKEBZ + GRZ SVR12 N=11 Drug DosingGrazoprevir 100 mg once daily and Elbasvir 50 mg once daily; given as separate medications in Immediate treatment and Intensive PK arms; given as fixed dose combination in Deferred arm Source: Roth D, et al. Lancet 2015;386:1537-45.

  4. Elbasvir + Grazoprevirin HCV GT1 and Renal DiseaseC-SURFER Study: Participants Source: Roth D, et al. Lancet 2015;386:1537-45.

  5. Elbasvir + Grazoprevirin HCV GT1 and Renal DiseaseC-SURFER Study: Results C-SURFER: SVR12 Results Modified analysis excluded patients who did not receive ≥1 dose of drug or who died or discontinued early for reasons unrelated to HCV treatment. Source: Roth D, et al. Lancet 2015;386:1537-45.

  6. Elbasvir + Grazoprevirin HCV GT1 and Renal DiseaseC-SURFER Study: Safety § Among patients not on dialysis at baseline. Source: Roth D, et al. Lancet 2015;386:1537-45.

  7. Elbasvir + Grazoprevirin HCV GT1 and Renal DiseaseC-SURFER Study: Conclusions Source: Roth D, et al. Lancet 2015;386:1537-45.

More Related